LoadingLoadingLoadingNet selling: insiders sold $50M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full results8 funds hold a position and insiders have been net selling.
Buys/Adds (1)
Citadel
$251.3M
added
Sells/Trims (2)
Lone Pine
$426.2M
sold
Qube Research
$109.8M
trimmed
Top-trader positions in THC could not be loaded.
Hyperliquid positioning - not every stock is covered
Last report
Jul 23, 2026
Period ending
Jun 30, 2026
Earnings per share
$4.08 expected
Revenue
Financial statements: Alpha Vantage
Estimates as of Oct 24, 2026
EPS expected
$4.03 to $5.04
Revenue expected
18 analysts
Last 30 days
Split both ways
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / income | Surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Jul 23, 2026 | $6.12 / $4.08Alpha Vantage | +50.00% beat | $5.63B No estimate | Unavailable |
| Mar 31, 2026 | Apr 30, 2026 | $4.82 / $4.17Alpha Vantage | +15.59% beat | $5.37B No estimate | Unavailable |
| Dec 31, 2025 | Feb 11, 2026 | $4.70 / $4.07Alpha Vantage | +15.48% beat | $5.53B No estimate | Unavailable |
| Sep 30, 2025 | Oct 28, 2025 | $3.70 / $3.35Alpha Vantage | +10.45% beat | $5.29B No estimate | Unavailable |
| Jun 30, 2025 | Jul 22, 2025 | $4.02 / $2.87Alpha Vantage | +40.07% beat | $5.27B No estimate | Unavailable |
| Mar 31, 2025 | Apr 29, 2025 | $4.36 / $3.13Alpha Vantage | +39.30% beat | $5.22B No estimate | Unavailable |
| Dec 31, 2024 | Feb 12, 2025 | $3.44 / $2.83Alpha Vantage | +21.45% beat | $5.07B No estimate | Unavailable |
| Sep 30, 2024 | Oct 29, 2024 | $2.93 / $2.37Alpha Vantage | +23.63% beat | $5.12B No estimate | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue and income use company releases, SEC filings, Alpha Vantage or Yahoo Finance. Non-USD revenue carries its currency code. Comparisons require a paired release estimate.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $5.29B | $5.53B | $5.37B | $5.63B |
| Cost of what it sold | $2.20B | $4.66B | $4.49B | $4.60B |
| Gross profit | $3.08B | $869.0M | $882.0M | $1.02B |
| What it spent | ||||
| Sales and admin | $2.20B | $2.22B | $2.17B | $2.23B |
| Other operating costs | — | -$780.0M | $2.31B | $2.37B |
| Total operating expenses | $2.20B | $1.44B | $4.49B | $4.60B |
| What was left | ||||
| Operating profit | $889.0M | $869.0M | $882.0M | $1.02B |
| Interest on debt | $206.0M | $205.0M | $205.0M | $204.0M |
| Profit before tax | $712.0M | $681.0M | $1.13B | $1.34B |
| Tax | $133.0M | $37.0M | $226.0M | $295.0M |
| Net profit | $342.0M | $371.0M | $702.0M | $826.0M |
| EBITDA | $1.14B | $1.12B | $1.57B | $1.24B |
This stock is in a strong uptrend.
Trend
Strong uptrend
100 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
Tenet Healthcare Corporation Estimates – TRADEGATE:THC1
NeutralOct 23Tenet Healthcare rated Buy after strong Q2 results and margin growth, with attractive valuation and growth prospects.
NeutralOct 22Tenet Healthcare (THC) Stock Dips While Market Gains: Key Facts
NeutralOct 21Investors Heavily Search Tenet Healthcare Corporation (THC): Here is What You Need to Know
Leans bullishOct 21Zacks cuts Tenet estimate as Tenet Healthcare stock awaits results
Leans bearishOct 20Tenet Healthcare lifts EBITDA outlook. October 29 results test Tenet Healthcare stock
BullishOct 18Form PRE 14A Tenet Healthcare Corporation For: 16 October By Investing.com
NeutralOct 18Learn Why The Bull Case For Tenet Healthcare Stock Could Change Following Guidance Raise
Leans bullishOct 17